{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:23:34Z","timestamp":1777868614880,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13099-8","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T08:55:15Z","timestamp":1775206515000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence and factors associated with drug resistance mutations among HIV\u2009\u2212\u20091 patients failing to achieve virological suppression on second line treatment in Tanzania"],"prefix":"10.1186","volume":"26","author":[{"given":"Mabula M.","family":"Mabelele","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mukasa","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mandela C.","family":"Makakala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatma","family":"Bakshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Adebayo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samina","family":"Somji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"key":"13099_CR1","unstructured":"Unaids. F A C T S H E E. T 2 0 2 2."},{"key":"13099_CR2","unstructured":"NBS | The Tanzania HIV Impact Survey. https:\/\/www.nbs.go.tz\/statistics\/topic\/the-tanzania-hiv-impact-survey. Accessed 4 Mar 2026."},{"key":"13099_CR3","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1097\/QAD.0b013e32833af85d","volume":"24","author":"KM Johnston","year":"2010","unstructured":"Johnston KM, Levy AR, Lima VD, Hogg RS, Tyndall MW, Gustafson P, et al. Expanding access to HAART: A cost-effective approach for treating and preventing HIV. AIDS. 2010;24:1929\u201335. https:\/\/doi.org\/10.1097\/QAD.0b013e32833af85d.","journal-title":"AIDS"},{"key":"13099_CR4","unstructured":"UNAIDS. data-book-2022_en."},{"key":"13099_CR5","unstructured":"90-90-90. - An ambitious treatment target to help end the AIDS epidemic | UNAIDS. https:\/\/www.unaids.org\/en\/resources\/documents\/2017\/90-90-90. Accessed 7 Mar 2023."},{"key":"13099_CR6","doi-asserted-by":"publisher","first-page":"21133","DOI":"10.7448\/IAS.19.1.21133","volume":"19","author":"M Sidib\u00e9","year":"2016","unstructured":"Sidib\u00e9 M, Loures L, Samb B. The UNAIDS 90-90-90 target: a clear choice for ending AIDS and for sustainable health and development. J Int AIDS Soc. 2016;19:21133. https:\/\/doi.org\/10.7448\/IAS.19.1.21133.","journal-title":"J Int AIDS Soc"},{"key":"13099_CR7","unstructured":"HIV\/AIDS JUNP on. The path that ends AIDS: 2023 UNAIDS global AIDS update. 2023."},{"key":"13099_CR8","unstructured":"NACP-National AIDS Control Programme. Tanzania national guidelines for the management of HIV and AIDS, 7th edition | GPC. 2019. https:\/\/hivpreventioncoalition.unaids.org\/en\/resources\/tanzania-national-guidelines-management-hiv-and-aids-7th-edition. Accessed 19 Aug 2024."},{"key":"13099_CR9","unstructured":"WHO, HIV DRUG RESISTANCE HIV DRUG RESISTANCE. REPORT 2021. 2021."},{"key":"13099_CR10","doi-asserted-by":"publisher","unstructured":"Misbah M, Poonam G, Roy G, Suresh K, Husain M. Drug resistance mutations in protease gene of HIV-1 subtype C infected patient population. Virusdisease 32. https:\/\/doi.org\/10.1007\/s13337-021-00725-z.","DOI":"10.1007\/s13337-021-00725-z"},{"key":"13099_CR11","doi-asserted-by":"publisher","unstructured":"Lippman SA, Mooney AC, Puren A, Hunt G, Grignon JS, Prach LM, et al. The role of drug resistance in poor viral suppression in rural South Africa: findings from a population-based study. BMC Infect Dis. 2020;20. https:\/\/doi.org\/10.1186\/S12879-020-4933-Z.","DOI":"10.1186\/S12879-020-4933-Z"},{"key":"13099_CR12","unstructured":"NACP-National AIDS Control Programme. Acquired HIV Drug Resistance among Children and Adults Receiving Antiretroviral Therapy in Tanzania: A National Representative Survey Report Report Draft 1 Issued \u2013 October, 2021 \u2013 NACP-National AIDS Control Programme. 2021. https:\/\/nacp.go.tz\/download\/acquired-hiv-drug-resistance-among-children-and-adults-receiving-antiretroviral-therapy-in-tanzania-a-national-representative-survey-report-report-draft-1-issued-october-2021\/. Accessed 19 Aug 2024."},{"key":"13099_CR13","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1111\/TMI.13131","volume":"23","author":"F Fily","year":"2018","unstructured":"Fily F, Ayikobua E, Ssemwanga D, Nicholas S, Kaleebu P, Delaugerre C, et al. HIV-1 drug resistance testing at second-line regimen failure in Arua, Uganda: avoiding unnecessary switch to an empiric third-line. Trop Med Int Health. 2018;23:1075\u201383. https:\/\/doi.org\/10.1111\/TMI.13131.","journal-title":"Trop Med Int Health"},{"key":"13099_CR14","doi-asserted-by":"publisher","unstructured":"Scriven YA, Mulinge MM, Saleri N, Luvai EA, Nyachieo A, Maina EN, et al. Prevalence and factors associated with HIV-1 drug resistance mutations in treatment-experienced patients in Nairobi, Kenya a cross-sectional study. 2021. https:\/\/doi.org\/10.1097\/MD.0000000000027460.","DOI":"10.1097\/MD.0000000000027460"},{"key":"13099_CR15","doi-asserted-by":"publisher","unstructured":"Chimbetete C, Katzenstein D, Shamu T, Spoerri A, Estill J, Egger M, et al. Open forum infectious diseases \u00ae HIV-1 drug resistance and third-line therapy outcomes in patients failing second-line therapy in Zimbabwe. https:\/\/doi.org\/10.1093\/ofid\/ofy005.","DOI":"10.1093\/ofid\/ofy005"},{"issue":"Suppl 1","key":"13099_CR16","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/HIV.13252","volume":"23","author":"L Gao","year":"2022","unstructured":"Gao L, Xia H, Zeng R, Wu Y, Zaongo SD, Hu Y, et al. Pre-treatment and acquired antiretroviral drug resistance among people living with HIV in Tianjin, China. HIV Med. 2022;23(Suppl 1):84\u201394. https:\/\/doi.org\/10.1111\/HIV.13252.","journal-title":"HIV Med"},{"key":"13099_CR17","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1093\/JAC\/DKW051","volume":"71","author":"C Hawkins","year":"2016","unstructured":"Hawkins C, Ulenga N, Liu E, Aboud S, Mugusi F, Chalamilla G, et al. HIV virological failure and drug resistance in a cohort of Tanzanian HIV-infected adults. J Antimicrob Chemother. 2016;71:1966\u201374. https:\/\/doi.org\/10.1093\/JAC\/DKW051.","journal-title":"J Antimicrob Chemother"},{"key":"13099_CR18","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/hiv.13006","volume":"22","author":"J Ross","year":"2021","unstructured":"Ross J, Jiamsakul A, Kumarasamy N, Azwa I, Merati TP, Do CD, et al. Virological failure and HIV drug resistance among adults living with HIV on second-line antiretroviral therapy in the Asia-Pacific. HIV Med. 2021;22:201\u201311. https:\/\/doi.org\/10.1111\/hiv.13006.","journal-title":"HIV Med"},{"key":"13099_CR19","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12981-017-0161-z","volume":"14","author":"EM Etta","year":"2017","unstructured":"Etta EM, Mavhandu L, Manhaeve C, Mcgonigle K, Jackson P, Rekosh D, et al. High level of HIV-1 drug resistance mutations in patients with unsuppressed viral loads in rural northern South Africa. AIDS Res Ther. 2017;14:36. https:\/\/doi.org\/10.1186\/s12981-017-0161-z.","journal-title":"AIDS Res Ther"},{"key":"13099_CR20","doi-asserted-by":"publisher","unstructured":"Kaleebu P, Kirungi W, Watera C, Asio J, Lyagoba F, Lutalo T, et al. Virological response and antiretroviral drug resistance emerging during antiretroviral therapy at three treatment centers in Uganda. PLoS ONE. 2015;10. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0145536.","DOI":"10.1371\/JOURNAL.PONE.0145536"},{"key":"13099_CR21","doi-asserted-by":"publisher","unstructured":"Oliveira MI, De Souza Junior VR, De Lacerda Vidal CF, De Ara\u00fajo PSR. Virologic suppression in response to antiretroviral therapy despite extensive resistance within HIV-1 reverse transcriptase after the first virologic failure. BMC Infect Dis. 2018;18. https:\/\/doi.org\/10.1186\/S12879-018-3400-6.","DOI":"10.1186\/S12879-018-3400-6"},{"key":"13099_CR22","doi-asserted-by":"publisher","unstructured":"Karade SK, Ghate MV, Chaturbhuj DN, Kadam DB, Shankar S, Gaikwad N, et al. Cross-sectional study of virological failure and multinucleoside reverse transcriptase inhibitor resistance at 12 months of antiretroviral therapy in Western India. Medicine. 2016;95. https:\/\/doi.org\/10.1097\/MD.0000000000004886.","DOI":"10.1097\/MD.0000000000004886"},{"key":"13099_CR23","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1128\/AAC.47.11.3377-3383.2003","volume":"47","author":"K Diallo","year":"2003","unstructured":"Diallo K, G\u00f6tte M, Wainberg MA. Molecular Impact of the M184V Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase. Antimicrob Agents Chemother. 2003;47:3377\u201383. https:\/\/doi.org\/10.1128\/AAC.47.11.3377-3383.2003.","journal-title":"Antimicrob Agents Chemother"},{"key":"13099_CR24","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/J.JCLINEPI.2022.02.005","volume":"148","author":"A Hauser","year":"2022","unstructured":"Hauser A, Goldstein F, Reichmuth ML, Kouyos RD, Wandeler G, Egger M, et al. Acquired HIV drug resistance mutations on first-line antiretroviral therapy in Southern Africa: Systematic review and Bayesian evidence synthesis. J Clin Epidemiol. 2022;148:135\u201345. https:\/\/doi.org\/10.1016\/J.JCLINEPI.2022.02.005.","journal-title":"J Clin Epidemiol"},{"key":"13099_CR25","doi-asserted-by":"publisher","unstructured":"Boucher S, Recordon-Pinson P, Ragnaud JM, Dupon M, Fleury H, Masquelier B. HIV-1 reverse transcriptase (RT) genotypic patterns and treatment characteristics associated with the K65R RT mutation. https:\/\/doi.org\/10.1111\/j.1468-1293.2006.00379.x.","DOI":"10.1111\/j.1468-1293.2006.00379.x"},{"key":"13099_CR26","doi-asserted-by":"publisher","unstructured":"Musengimana G, Tuyishime E, Kiromera A, Malamba SS, Mulindabigwi A, Habimana MR, et al. Acquired HIV drug resistance among adults living with HIV receiving first-line antiretroviral therapy in Rwanda: a cross-sectional nationally representative survey. Antivir Ther. 2022;27. https:\/\/doi.org\/10.1177\/13596535221102690.","DOI":"10.1177\/13596535221102690"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13099-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13099-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13099-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:12:38Z","timestamp":1777551158000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13099-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13099"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13099-8","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]},"assertion":[{"value":"23 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki for all procedures involving human participants and\/or human data. Ethical approval was obtained from the Aga Khan University Ethical Review Committee, East Africa (AKU-ERC, EA; Reference No. AKU\/2023\/024\/fb\/010\/017). The study utilized routinely collected clinical data and laboratory results from specimens obtained during standard clinical care and posed minimal risk to participants. Consequently, the requirement for individual informed consent was deemed unnecessary according to national regulations and waived by the Aga Khan University Ethical Review Committee, East Africa (AKU-ERC, EA).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"863"}}